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Abstract 
 Metallothionein (MT) is a small, thiol rich protein released into the extracellular 
environment in response to stress. Elevated expression of MT has been linked to many 
inflammatory diseases including inflammatory bowel diseases, diabetes, and cancer. In breast 
cancer, high expression of MT has been associated with poor patient prognosis. Previous studies 
have shown that MT acts as a chemoattractant in lymphocytes, and that UC1MT, a monoclonal 
anti-MT antibody, can block this chemotactic response. In addition, it has been shown that both 
Cholera toxin and Pertussis toxin, which are known antagonists of G-protein coupled receptors, 
can inhibit MT-mediated chemotaxis. Here, I investigate the signaling pathways of MT-mediated 
chemotaxis using small molecule inhibitors in cellular models of inflammation and breast cancer. 
I also examine the chemotactic potential of MT in mammary tumor cell lines and the ability of 
UC1MT to block this chemotactic response. Experiments revealed that MT is chemotactic in 
mammary tumor cell lines. I have found that, like in lymphocytes, MT interacts with receptor 
CXCR4 in breast cancer models to initiate the chemotactic response. Studies conducted using 
MT peptides revealed that MT’s N-terminus is likely involved in the binding of this protein to its 
receptor. MT-mediated chemotaxis in both immune cells and breast cancer cell models can be 
blocked using CK-666 and U73122, but not with PD98059, which suggests that the Arp2/3 
complex and phospholipase C (PLC) are involved in MT’s chemotactic signaling pathways, but 
that mitogen activated kinase kinase (MEK) is not. Finally, I found that UC1MT can block MT-
mediated chemotaxis in mammary tumor cell lines. This suggests that UC1MT may be a useful 
therapeutic to inhibit breast cancer metastasis. 
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Introduction 
Metallothionein: Background and Significance  
Metallothionein (MT), is a low molecular weight, thiol-rich protein, that is released by 
cells into the extracellular environment as a response to stress1. MT is highly conserved across 
many species, and in mammals there are four isoforms of the protein. MT-1 and MT-2 are 
expressed at low levels in almost all cell types throughout an organism, while MT-3 and MT-4 
have more tissue specific expression2. The experiments conducted for this study focused on the 
MT-1 isoform, which will be referred to as MT from this point forward. Traditionally, MT has 
been studied in the intracellular environment and has been shown to play a role in metal 
homeostasis by interacting with divalent metal cations such as zinc, copper, cadmium, and 
mercury via the thiols present in its structure3. MT forms two metal binding domains, the C-
terminal α-domain and the N-terminal β-domain (Figure 1). The α-domain is comprised of 
amino acids 31-61 and is capable of binding four divalent metals. The β-domain is comprised of 
amino acids 1-30 and can bind three divalent metals4,5. 
 
Figure 1. Mammalian Metallothionein Structure with Metal Binding Pockets6 
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Even though MT is typically studied in the intracellular environment, it also plays a 
significant role in the extracellular environment. It has been shown that MT has many 
immunomodulatory effects on lymphocytes7. MT plays a role in CD4+ T cell differentiation, and 
CD8+ cytotoxic T cell and dendritic cell function8,9. It has also been shown that MT exposure 
synergistically enhances T and B cell proliferation when used in conjunction with Concanavalin 
A and Lipopolysaccharide respectively10. 
Chemotaxis is defined as directional movement of cells or organisms in response to a 
chemical or other stimulus. The Lynes Lab has shown that immune cells migrate chemotactically 
towards increasing concentrations of MT and that MT exposure results in an increase in F-actin 
levels in cells11. The addition of UC1MT, an anti-MT monoclonal antibody, alters the 
immunomodulatory effect of MT12,13. In regard to this study, it is of particular interest that 
UC1MT can block MT’s chemotactic effect in Jurkat T cells11. 
G-protein coupled receptors (GPCRs) and their downstream signaling pathways are 
commonly involved in the initiation of a chemotactic response (Figure 2)14. A previous study 
done in the Lynes lab suggests that a GPCR may be involved in signaling associated with MT-
mediated chemotaxis since the chemotactic response to MT is blocked by the presence of either 
pertussis toxin or cholera toxin, both of which are known antagonists of GPCR mediated 
events11. These findings prompted my interest in investigating the signaling pathways of MT-
mediated chemotaxis and the potential role of GPCRs in initiating these pathways.  
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Figure 2. Schematic of GPCR Signaling Pathways Involved in Chemotaxis14 
 
Metallothionein and Inflammatory Diseases 
MT has been linked to the progression of inflammation associated with disease in many 
organ systems. Cancer, neuroinflammatory diseases, inflammatory bowel disease, and diabetes 
have all been linked to elevated MT expression15,16. 
 MT has been found to be upregulated in many neurodegenerative diseases including 
Alzheimer’s Disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). In 
addition, acute and chronic brain injury has been linked to increased levels of MT due to 
neuroinflammation and oxidative stress associated with these conditions15,17.  
Inflammatory Bowel Diseases (IBD) such as Crohn’s Disease and ulcerative colitis are 
chronic intestinal inflammatory diseases with unclear origins, however it is thought that genetic 
factors, environmental factors, and the gut microbiota contribute to the disease phenotype18,19. 
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Studies have shown that MT expression levels are dysregulated in patients with IBD20. Similarly, 
murine colitis models show upregulation of MTs21. Experiments conducted in murine Dextran 
Sodium Sulphate (DSS)-induced colitis model suggest that UC1MT may be a useful tool as a 
preventative and therapeutic treatment for colitis as it reduces cell infiltration of the intestinal 
epithelium, which is characteristic of inflammation associated with colitis22. 
Type 1 Diabetes (T1D) is an autoimmune disease characterized by a loss of tolerance to 
insulin-producing pancreatic β cells, in which the immune system targets these cells for 
destruction. In T1D, pancreatic β cells are completely lost, which results in insulin deficiency 
and dysregulation of glucose metabolism23.  In a study examining the expression of MT at 
different stages of T1D development, it was shown that MT-1 and MT-3 levels were increased in 
patients with longstanding T1D compared to patients with early onset of the disease and control 
patients24. Experiments conducted in non-obese diabetic mice, a mouse model commonly used 
for T1D research, have shown that administration of UC1MT results in a decreased blood 
glucose level and decreased insulitis score compared to administration of an isotype control25, 
indicating that UC1MT may have a useful clinical application in the prevention of this disease. 
 
Metallothionein and Cancer 
Increased expression of MT has been linked to the manifestation of many different 
cancers, including glioblastoma, prostate cancer, ovarian, and breast cancer26–29. The increased 
expression of MT in each of these types of cancer indicate a worse prognosis for the patient27,30. 
MT can inhibit apoptosis and protect cells against radiation and cytotoxic alkylating agents. 
Because many chemotherapy agents fall into this category, MT can protect cells, including 
cancer cells, from the drugs used to eradicate them27. This association between increased MT 
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expression and decreased chemotherapy efficacy highlights a gap in current cancer treatment 
protocols, one that can potentially be filled by manipulation of the extracellular pool of MT with 
UC1MT. 
 
Metallothionein and Breast Cancer 
 Breast Cancer represents a significant health risks, with an estimated 266,120 new cases 
and accounting for an estimated 40,920 deaths in the United States in 201831. With one in eight 
women developing the disease in her lifetime, breast cancer is the most common cancer 
diagnosed and second leading cause of death in women. While 62% of breast cancer cases 
involve only a primary tumor, 31% of cases involved metastases to local lymph nodes, and 6% 
of cases involve metastases to distant locations in the body. Once the tumor has extended beyond 
its primary location, five-year survival rates for patients drop significantly31. Even with modern 
therapeutics, metastasis still poses a significant challenge when treating patients with breast 
cancer and serves as an important target for new drug development. 
Several studies have shown that inflammation plays a key role in the progression of 
breast cancer32–35. Of these studies, the one conducted by Pierce is of particular interest as it 
suggests that circulating markers of inflammation, including pro-inflammatory cytokines, might 
indicate disease recurrence even without a history of metastasis or the presence of other clinical 
indications of cancer32. 
In breast cancer, increased expression of MT has been associated with greater tumor 
grade30. In addition, high levels of MT in breast cancer have been linked to worse tumor 
prognosis, including increased likelihood of local tumor recurrence, shorter disease-free interval, 
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and decreased survival36. MT’s role in inflammation and its association with poor prognosis in 
breast cancer patients suggests that manipulation of this stress response protein may improve 
patient outcomes. 
In this study, I will investigate the mechanism by which MT initiates a chemotactic 
response in immune cells and thus contributes to the inflammatory environment associated with 
many disease phenotypes. I will also examine this phenomenon in mammary tumor cell models 
to determine if using UC1MT to manipulate the extracellular pool of MT would be a useful 
therapeutic approach to inhibit breast cancer metastasis. 
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Materials and Methods 
Proteins, Antibodies, and Small Molecule Inhibitors 
MT-1 from rabbit liver (Cat# ALX-202-072-0000), CK-666 (Cat# ALX-270-506-M002), 
U73122 (Cat# BML-ST391-0005), and PD98059 (Cat# BML-EI360-0005) were obtained from 
Enzo Life Sciences. Recombinant human SDF-1α was obtained from Shenandoah (Cat# 100-20). 
AMD3100 (Cat# A5602) was obtained from Sigma Life Sciences. Thirteen different MT 
peptides [MT1-10 (Cat# 65595-1), MT4-12 (Cat# 65595-2), MT11-20 (Cat# 65595-3), MT16-25 (Cat# 
65595-4), MT22-31 (Cat# 58274), MT25-35 (Cat#65595-5), MT31-40 (Cat# 65595-6), MT35-43 (Cat# 
65595-7), MT40-49 (Cat# 65595-8), MT46-55 (Cat# 65595-9), MT51-61 (Cat# 65595-10), MTsc1 
(Cat# 58242-1), and MTsc2 (Cat# 65595-11)] were designed based on the rabbit MT-1 sequence 
(Table 1) as described in Bhandari, 2018 and purchased from AnaSpec. UC1MT, a monoclonal 
anti-MT antibody, was obtained from Thermo Fisher Scientific.  
 
Table 1. Rabbit MT-1 and MT Peptide Sequences 
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Cell Culture 
Jurkat T Cells (ATCC TIB-152), a human T lymphocyte leukemia cell line, were cultured 
in RPMI-1640 (Sigma, Cat# 8758) with 1% penicillin/streptomycin (Cellgro, Cat# 30-002-CI), 
1mM Sodium Pyruvate (MP Biomedicals, Cat# 1682049), 1mM HEPES Buffer (Corning, Cat# 
25-060-Cl), 4mM L-Glutamine (Sigma, Cat# 56-58-9), and 10% heat inactivated Fetal Bovine 
Serum (Atlanta Biologicals, Cat# S11550) at 37°C with 5% CO2. Cells were maintained at a 
concentration of between 105 and 106 cells per milliliter by aspirating cells in spent media and 
replenishing with fresh media using sterile technique.  
MDA-MB-231 (ATCC HTB-26), a triple negative human epithelial breast cancer cell 
line, was cultured in high glucose Dulbecco's Modified Eagle Medium (Gibco Life Sciences, 
Cat# 11965118) with 1% penicillin/streptomycin, 4mM L-Glutamine, and 10% heat inactivated 
Fetal Bovine Serum at 37°C with 5% CO2. Cells were maintained at a concentration of between 
105 and 106 cells per milliliter by aspirating cells in spent media and replenishing with fresh 
media using sterile technique. Because MDA-MB-231 cells are adherent, a cell scraper 
(Fisherbrand, Cat# 08-100-241) was used to dislodge them from the bottom of the flask before 
each passage. 
419, a murine mammary tumor cell line derived from the MMTV-PyMT mouse model, 
was obtained from David Lawrence, PhD (New York State Department of Health Wadsworth 
Center, Albany NY) and cultured in high glucose Dulbecco's Modified Eagle Medium with 1% 
penicillin/streptomycin and 10% heat inactivated Fetal Bovine Serum at 37°C with 5% CO2. 
Cells were maintained at a concentration of between 105 and 106 cells per milliliter by aspirating 
cells in spent media and replenishing with fresh media using sterile technique. Because 419 Cells 
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are a highly adherent cell line, they were treated with Trypsin-EDTA (Sigma Life Sciences, Cat# 
T2601) for five minutes then dislodged using a cell scraper before each passage. 
 
Primary Splenocyte Isolation 
C57BL/6J mice were euthanized by CO2 asphyxiation. The spleen was harvested using 
sterile dissection technique. A single cell suspension was made using a disposable pestle tissue 
grinder. Cell suspension was put through a 40µm pore cell strainer (Fisherbrand, Cat# 22363547) 
and washed with 4mL of splenocyte media (RPMI-1640 with 1% penicillin/streptomycin, 1mM 
sodium pyruvate, 1mM L-Glutamine, 0.1 mM non-essential amino acids (Gibco, Cat# 01216), 
and 10% heat inactivated Fetal Bovine Serum). Cells were washed with 10mL of splenocyte 
media then the red blood cells were lysed using sterile Ammonium-Chloride-Potassium Lysis 
Buffer (150mM ammonium chloride, 10mM potassium bicarbonate, and 0.1mM Na2EDTA at 
pH 7.2). Cells were washed with 10mL splenocyte media. Splenocytes were resuspended in 
10mL fresh media and put through a 40µm pore cell strainer. Cell density and viability were 
calculated using a hemocytometer and trypan blue (Sigma Life Sciences, Cat# T8154) exclusion 
staining. 
 
Boyden Chamber Assay 
The Boyden Chamber Assay was conducted in either the 48 (Neuro Probe, Cat# AP48) or 
96 (Neuro Probe, Cat# AP96) well Micro Chemotaxis Chamber. Chemoattractants were diluted 
to working concentrations in appropriate media. 25µL of chemoattractant were added to the 
bottom wells of the Boyden Chamber. Media alone served as a negative control. Incubation 
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times and membrane pore size were optimized for each cell line used. For Jurkat T cells, 
experiments were conducted in the 48 well chamber using 5µm pore membranes (Neuro Probe, 
Cat# PFB5). For primary mouse splenocytes, experiments were conducted in the 48 well 
chamber using 3µm pore membranes (Neuro Probe, Cat# PFB3). For MDA-MB-231 cells, 
experiments were conducted in the 48 well chamber using 8µm pore membranes (Neuro Probe, 
Cat# PFB8) coated with 10µg/mL Fibronectin (Sigma Life Sciences, Cat# F0895) in phosphate 
buffered saline (PBS) overnight prior to their use.  For 419 cells, MT peptide experiments were 
conducted in the 96 well chamber, while all other experiments were conducted in the 48 well 
chamber. 3µm pore membranes (Neuro Probe, Cat# PFB3 or PFD3) were used for experiments 
using 419 cells. After chamber assembly, 50µl of cells in single cell suspension at 2x106 
cells/mL were added to the wells of the upper chamber. For experiments involving small 
molecule inhibitors, cells were pre-incubated with non-toxic doses of either AMD3100 (Figure 
S1), CK-666 (Figure S2), U73122 (Figure S3), or PD98059 (Figure S4). After pre-incubation, 
cells were washed and resuspended at 2 million cells/mL to be loaded into the wells of the upper 
chamber.  Chambers were incubated at 37°C with 5% CO2 for 3 hours (Jurkat T cells, primary 
mouse splenocytes, and 419 cells) or 6 hours (MDA-MB-231 cells). After incubation, chambers 
were disassembled, and a cell scraper was used to remove the cells from the top side of the 
membrane. Cells on the underside of the membrane were stained using the Hema 3 stain set 
(Protocol, Cat# 122-911) and were counted under the light microscope at 10x. 
 
Data Analysis 
Data was analyzed using the GraphPad Prism 8 software. Each experiment was analyzed 
using ordinary one-way analysis of variance (ANOVA) followed by Tukey’s Multiple 
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Comparisons Test to determine statistical significance. For each statistical test, ns (no 
significance) indicates a p value of greater than 0.05, * indicates a p value of less than or equal to 
0.05, ** indicates a p value of less than or equal to 0.01, *** indicates a p value of less than or 
equal to 0.001, and **** indicates a p value of less than or equal to 0.0001. There was a 
minimum of three replicates for each condition in every experiment and the average of these 
values was calculated to be used for analysis. All values are displayed with standard deviation. 
Graphs are representative results of three independent experiments. 
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Results 
MT is Chemotactic in Mammary Tumor Cell Lines 
 Previous research conducted in the Lynes Lab has established that MT acts as a 
chemoattractant to lymphocytes11,25. As a result, immune cells migrate towards increasing 
concentrations of MT in the body, which contributes to inflammation at sites of high MT 
expression. This phenomenon contributes to many inflammatory diseases including 
inflammatory bowel disease, diabetes, and many types of cancer15. As mentioned earlier, MT 
expression is associated with worse outcomes in cancer patients, including those with breast 
cancer27,30. MT expression contributes to inflammation found in the tumor micro environment 
which plays a key role in the development of the disease32–35. While the chemotactic role of MT 
in the extracellular environment has been studied extensively in Bhandari, 2018, these studies 
did not address the role of MT-mediated chemotaxis in breast cancer cells.  
 For these experiments, I have used two mammary tumor cell lines as models for breast 
cancer. MDA-MB-231is a triple negative human epithelial breast cancer cell line commonly 
used in breast cancer research. I selected this cell line to model breast cancer in this project as 
triple negative breast cancer is particularly challenging to treat with the current available 
therapeutics, so it is important to continue to develop new options for treating this disease 
phenotype. 419, a murine mammary tumor cell line derived from MMTV-PyMT mice served as 
a second model of mammary tumorigenesis. I have selected this murine cell line to model 
mammary tumorigenesis as mice are commonly used animal models in breast cancer research, 
and the MMTV-PyMT mouse model, from which this cell line is derived from, develops 
particularly aggressive mammary tumors, which are challenging to treat. 
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 In Figure 3, I have conducted experiments to determine if MT is chemotactic in breast 
cancer. If MT can induce chemotaxis in these mammary tumor cell lines, this may suggest that 
MT plays a role in breast cancer metastasis, thereby resulting in a worse prognosis for the 
patient.  
 Using the Boyden Chamber assay, I was able to examine the effect of MT on both MDA-
MB-231 cells and 419 cells. For these experiments, either media alone or MT was loaded into 
the bottom wells of the chamber. The chamber was then assembled and MDA-MB-231 cells 
(Figure 3A) or 419 cells (Figure 3B) were loaded with and without MT into the wells of the 
upper chamber. When MT was loaded into the wells of the bottom chamber, there was a 
statistically significant increase in the average number of cells migrated per well in both MDA-
MB-231 cells and 419 cells, however when MT was loaded into the wells of the upper chamber 
with the cells, there was no increase in cell migration. These results indicated that MT is in fact 
chemotactic in MDA-MB-231 cells and 419 cells. Because MT is chemotactic in these models of 
breast cancer, it suggests that MT may play a role in breast cancer metastasis. 
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Figure 3. MT is Chemotactic in Mammary Tumor Cell Lines. 
The bottom chamber was loaded with either 10µM MT or media alone. Boyden chamber was 
assembled using an 8µm pore (A) or 3µm pore (B) membrane. 8µm pore membranes were 
coated in 10µg/mL fibronectin at 4°C overnight prior to use. MDA-MB-231 (A) or 419 (B) cells 
(2million cells/mL) were loaded into the top chamber with either 10µM MT or media alone. 
Boyden Chamber was incubated for 6 hours (A) or 3 hours (B) at 37°C in 5% CO2. Cells on the 
underside of the membrane were enumerated using a light microscope under 10x. One-way 
ANOVA followed by Tukey’s Multiple Comparisons Test was used to determine statistical 
significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs 
are representative of three independent experiments. 
 
 
A B 
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MT Peptides and the Chemotactic Response in Mammary Tumor Cell Lines 
 Previous studies in the Lynes Lab have shown that pre-incubation with MT can block 
SDF-1α-mediated chemotaxis in Jurkat T cells. This finding prompted the development of MT 
peptides using the sequence of MT-1 (Table 1) to determine which region of MT binds to its 
receptor(s) to initiate the chemotactic response.  Experiments conducted using Jurkat T cells 
indicated that the N-terminal region of MT interacts with its receptor25. In the experiments 
conducted in Figure 4, I used MT peptides to characterize MT’s interaction with its receptor in 
breast cancer using 419 cells as a model of mammary tumorigenesis. 
 In Figure 4A, I used the Boyden Chamber assay to determine if MT peptides are 
chemotactic in 419 cells. If any of the MT peptides are chemotactic, this would indicate that 
those amino acids are responsible for interacting with MT’s receptor(s) on the cell surface to 
initiate the chemotactic response. MT peptides, MT (MT control), or media alone (media 
control) were loaded into the wells of the bottom chamber. Boyden Chamber was assembled, and 
419 cells were loaded into the wells of the upper chamber. Results from this experiment showed 
that none of the MT peptides caused an increase in cell migration compared to the Media control, 
which suggests that they are not chemotactic on their own. While these results did not provide 
any information as to which amino acids interact with MT’s receptor, they do suggest that there 
is some important interaction between full-length MT and the receptor that shortened peptides 
alone cannot establish. 
 In Figure 4B, I investigated the ability of MT peptides to block MT-mediated chemotaxis 
in 419 cells. If any MT peptide occupies the binding site for MT on the receptor, it will inhibit 
MT binding, thus blocking MT’s chemotactic effect. 419 cells were pre-incubated with MT 
peptides, MT or media alone (MT control and Media control). The wells of the bottom chamber 
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were loaded with MT (MT peptides, MT, and MT Control) or media alone (Media control). The 
Boyden Chamber was assembled, and the wells of the top chamber were loaded with 419 cells. I 
found that pre-incubation with MT1-10, MT4-12, and MT11-20 results in a reduction in cell 
migration compared to the MT control, suggesting that these peptides can block MT-mediated 
chemotaxis.  
 In Figure 4C, I examined the ability of MT peptides to block Stromal Cell-Derived 
Factor-1α (SDF-1α)-mediated chemotaxis in 419 cells. The design of this experiment was 
similar to that of the experiment conducted in Figure 4B, however SDF-1α was used as the 
chemoattractant instead of MT. Since it has been shown that MT can block SDF-1α-mediated 
chemotaxis25, the ability of one (or more) of the MT peptides to block this response would 
indicate that that region of MT is responsible for binding to MT’s receptor(s). 419 cells were pre-
incubated with MT peptides, MT or media alone (SDF-1α control and Media control). The wells 
of the bottom chamber were loaded with SDF-1α (MT peptides, MT, and SDF-1α Control) or 
media alone (Media control). The Boyden Chamber was assembled, and the wells of the top 
chamber were loaded with 419 cells. I found that pre-incubation with MT1-10, MT4-12, and MT11-
20 results in a reduction in cell migration compared to the SDF-1α control, suggesting that these 
peptides can block SDF-1α-mediated chemotaxis. These results are consistent with those found 
in experiments using MT as the chemoattractant (Figure 4B). 
 While the MT peptides were not able to elicit a chemotactic response on their own, a few 
of peptides corresponding with the N-terminus of the protein (MT1-10, MT4-12, and MT11-20) were 
able to block both MT-mediated and SDF-1α-mediated chemotaxis in 419 cells. Taken together, 
the results from experiments conducted in Figure 4 suggest that there is some important 
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interaction between full-length MT and its receptor that is necessary to illicit the chemotactic 
response that MT peptides alone cannot establish, and that the N-terminus of MT is responsible 
for binding to its receptor.  
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Figure 4. MT Peptides and the Chemotactic Response in Mammary Tumor Cell Lines 
(A) Chemoattractants (100µg/mL MT peptides, 100µg/mL MT or media alone) were loaded into 
the bottom chamber. Boyden chamber was assembled using a 3µm pore membrane. 419 cells 
(2million cells/mL) were loaded into the upper chamber. (B) 419 cells were pre-incubated for 1 
hour with either 100µg/mL MT peptides, 100µg/mL MT or media alone (MT control and Media 
control) at 37°C in 5% CO2. 10µM MT (MT peptides, MT, and MT control) or media alone 
(Media control) was loaded into the bottom chamber. Boyden chamber was assembled using a 
A B 
C 
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3µm pore membrane. Cells were washed, resuspended at 2million cells/mL, and loaded into the 
upper chamber. (C) 419 cells were pre-incubated for 1 hour with either 100µg/mL MT peptides, 
100µg/mL MT or media alone (SDF-1α control and Media control) at 37°C in 5% CO2. 
100ng/mL SDF-1α (MT peptides, MT, and SDF-1α control) or media alone (Media control) was 
loaded into the bottom chamber. Boyden chamber was assembled using a 3µm pore membrane. 
Cells were washed, resuspended at 2million cells/mL, and loaded into the upper chamber. 
(A+B+C) Boyden chamber was incubated for 3 hours at 37°C in 5% CO2. Cells on the underside 
of the membrane were enumerated using a light microscope under 10x. Experimental conditions 
were compared to the Media control (A), the MT control (B) or the SDF-1α control (C) and One-
way ANOVA followed by Tukey’s Multiple Comparisons Test was used to determine statistical 
significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs 
are representative of three independent experiments. 
 
MT Interacts with CXCR4 to Initiate the Chemotactic Response in Mammary 
Tumor Cell Lines  
 Previous studies in the Lynes Lab have shown that MT can interfere with SDF-1α-
CXCR4 mediated chemotaxis25. In addition, it has been shown that MT-mediated chemotaxis 
can be blocked by Cholera toxin and Pertussis toxin, both of which are known antagonists of 
GPCRs11. These findings suggested that MT interacts with CXCR4 to initiate the chemotactic 
response. 
AMD3100 (AnorMeD 3100), originally known as JM3100, is a small molecule inhibitor 
of CXCR4 that was initially identified for its ability to target HIV viral protein gp120. Later 
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studies found that AMD3100 blocked the interaction between gp120 and chemokine receptor 
CXCR4, preventing the entry of HIV virus into the cell37,38. Currently, AMD3100 is being 
examined for its ability to act as an HIV entry inhibitor, to mobilize stem cells, and to treat 
leukemias and solid tumors39. 
AMD3100 has been shown to block MT-mediated chemotaxis in Jurkat T cells, which 
suggests that CXCR4 plays a role in MT’s chemotactic response in lymphocytes and thus 
inflammation associated with MT expression25. In these experiments, I will determine if 
AMD3100 also blocks MT-mediated chemotaxis in mammary tumor cell models. If AMD3100 
blocks MT-mediated chemotaxis in MDA-MB-231 cells and 419 cells, this would suggest that 
CXCR4 is involved in MT’s chemotactic signaling pathways in breast cancer. 
In Figure 5, MDA-MB-231 cells (Figure 5A) or 419 cells (Figure 5B) were pre-incubated 
with non-toxic doses of AMD3100 (Figure S1). MT control and Media control cells were pre-
incubated in media alone. MT (MT control and AMD3100) or media alone (Media control) was 
loaded into the wells of the bottom chamber. The Boyden Chamber was assembled, and cells 
were loaded into the wells of the upper chamber. Pre-incubation with AMD3100 results in a 
statistically significant decrease in the average number of cells migrated per well in both MDA-
MB-231 cells (Figure 5A) and 419 cells (Figure 5B).  
The fact that pre-incubation with AMD3100 blocks MT-mediated chemotaxis in 
mammary tumor cell models suggests that CXCR4 is involved in MT’s chemotactic signaling 
pathways. While CXCR4 may not be the only receptor that MT interacts with to initiate its 
chemotactic response, these results provide valuable insight into MT’s mechanism of action as a 
chemoattractant, which will help us understand how manipulating the extracellular pool of MT 
may have therapeutic benefits in breast cancer. 
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Figure 5. CXCR4 is Involved in MT-Mediated Chemotaxis in Mammary Tumor Cell Lines. 
Cells were pre-incubated with AMD3100 for 30 minutes at 37°C in 5% CO2. 20µg/mL 
AMD3100 was used with MDA-MB-231 cells (A), while 10µg/mL AMD3100 was used with 
419 cells (B) as determined by dose response and viability experiments (Fig. S1). Media and MT 
controls were pre-incubated under the same conditions in media alone. The bottom chamber was 
loaded with either 10µM MT (MT control and AMD3100) or media alone (Media control). 
Boyden chamber was assembled using an 8µm (A) or 3µm pore (B) membrane. 8µm pore 
membranes were coated in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed 
in media, resuspended at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber 
was incubated for 6 hours (A) or 3 hours (B) at 37°C in 5% CO2. Cells on the underside of the 
membrane were enumerated using a light microscope under 10x. One-way ANOVA followed by 
Tukey’s Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 
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0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three 
independent experiments. 
 
The Arp2/3 Complex is Involved in MT-Mediated Chemotaxis 
 Actin Related Protein 2/3 (Arp2/3) complex plays an important role in the regulation of 
the actin cytoskeleton by catalyzing actin filament nucleation. Arp2/3 bound to existing actin 
filaments interacts with ATP and nucleation-promoting factors to facilitate the addition of actin 
monomers to the filament40,41. As previously discussed, MT exposure results in an increase in F-
actin concentrations in cells11. This led to the hypothesis that the Arp2/3 complex is involved in 
MT’s chemotactic signaling pathways.  
 CK-666, a small molecule inhibitor of the Arp2/3 complex, was used to test this 
hypothesis. CK-666 inhibits the activity of the Arp2/3 complex by stabilizing the inactive state 
of the complex. CK-666 blocks the movement of both the Arp2 and the Arp3 subunits into the 
active conformation, thereby preventing the nucleation of actin filament42.  
 First, I examined the role of the Arp2/3 complex in MT-mediated chemotaxis as it relates 
to infiltration of immune cells and subsequent inflammation. For these experiments, I pre-
incubated Jurkat T cells (Figure 6A) or primary mouse splenocytes (Figure 6B) with nontoxic 
doses of CK-666 (Figure S2). MT control and Media control cells were pre-incubated in media 
alone. MT (MT control and CK-666) or media alone (Media control) was loaded into the wells 
of the bottom chamber. After the Boyden Chamber was assembled, cells were loaded into the 
wells of the top chamber. Pre-incubation with CK-666 results in a statistically significant 
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decrease in the average number of cells migrated per well in both Jurkat T cells (Figure 6A) and 
primary mouse splenocytes (Figure 6B).  
 Next, I examined the role of the Arp2/3 complex in MT-mediated chemotaxis as it relates 
to breast cancer metastasis. For these experiments, I pre-incubated MDA-MB-231 cells (Figure 
6C) or 419 cells (Figure 6D) with nontoxic doses of CK-666 (Figure S2). MT control and Media 
control cells were pre-incubated in media alone. MT (MT control and CK-666) or media alone 
(Media control) was loaded into the wells of the bottom chamber. After the Boyden Chamber 
was assembled, cells were loaded into the wells of the top chamber. Pre-incubation with CK-666 
results in a statistically significant decrease in the average number of cells migrated per well in 
both MDA-MB-231 cells (Figure 6C) and 419 cells (Figure 6D).  
 The fact that pre-incubation with CK-666 blocks MT-mediated chemotaxis in 
lymphocytes and mammary tumor cell lines suggests that the Arp2/3 complex is involved in 
MT’s chemotactic signaling pathways. This result is significant as it provides valuable insight 
regarding the mechanism by which MT induces chemotaxis. By understanding MT’s mechanism 
of action, we can identify the therapeutic opportunities of manipulating the extracellular pool of 
MT to reduce inflammation and prevent breast cancer metastasis. 
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Figure 6. Arp2/3 is Involved in MT-Mediated Chemotaxis. 
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D) 
were pre-incubated with 100µM CK-666 for 1 hour at 37°C in 5% CO2 as determined by dose 
response and viability experiments (Fig. S2). Media and MT controls were pre-incubated under 
the same conditions in media alone. The bottom chamber was loaded with either 10µM MT (MT 
control and CK-666) or media alone (Media control). Boyden chamber was assembled using an 
8µm (C), 5µM (A), or 3µm pore (B+D) membrane. 8µm pore membranes were coated in 
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10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2 
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours 
(A+B+D) or 6 hours (C) at 37°C in 5% CO2. Cells on the underside of the membrane were 
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s 
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** = 
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three independent 
experiments. 
 
Phospholipase C is Involved in MT-Mediated Chemotaxis 
 Phospholipase C (PLC) β has been shown to be involved in G-protein coupled receptor 
signaling pathways in T lymphocytes. GPCR subunit Gαi activates PLCβ and phosphoinositol-3-
kinase (PI3K) γ, which results in modification of the phospholipids produced by 
phosphatidylinositol 4,5-bisphosphate (PIP2). Subsequently, the hydrolysis of PIP2 results in the 
production of 1,4,5-triphosphate (IP3), which causes an increase in intracellular calcium. This 
PLCβ signaling cascade has been shown to be involved in the chemotactic response initiated by 
several different chemokines including  SDF-1α43. 
 To investigate the role of PLC in MT-mediated chemotaxis, I used small molecule 
inhibitor U73122. U73122 blocks PLC signaling by reducing the availability of PIP2, a substrate 
of the PLC signaling cascade44.  
 First, I conducted experiments using Jurkat T cells and primary mouse splenocytes to 
determine the involvement of PLC in MT-mediated chemotaxis in the infiltration of immune 
cells. Jurkat T cells (Figure 7A) and primary mouse splenocytes (Figure 7B) were pre-incubated 
Messina 32 
 
with non-toxic doses of U73122 (Figure S3). MT control and Media control cells were pre-
incubated in media alone. MT (MT control and U73122) or media alone (Media control) was 
loaded into the wells of the bottom chamber. After the Boyden Chamber was assembled, cells 
were loaded into the wells of the top chamber. Pre-incubation with U73122 results in a 
statistically significant decrease in the average number of cells migrated per well in both Jurkat T 
cells (Figure 7A) and primary mouse splenocytes (Figure 7B). 
  Next, I examined the role of PLC in MT-mediated chemotaxis as it relates to breast 
cancer metastasis. For these experiments, I pre-incubated MDA-MB-231 cells (Figure 7C) and 
419 cells (Figure 7D) with U73122 at non-toxic doses (Figure S3). MT control and Media 
control cells were pre-incubated in media alone. MT (MT control and U73122) or media alone 
(Media control) was loaded into the wells of the bottom chamber. Boyden chamber was 
assembled, and cells were loaded into the wells of the top chamber. Pre-incubation experiments 
showed that U73122 treatment results in a statistically significant decrease in the average 
number of cells migrated per well in both MDA-MB-231 cells (Figure 7C) and 419 cells (Figure 
7D). 
 Results from U73122 pre-incubation experiments indicate that U73122 can block MT-
mediated chemotaxis in both lymphocytes and mammary tumor cell lines, which suggests that 
PLC is involved in MT’s chemotactic signaling pathways. These experiments have provided 
valuable information regarding the mechanism by which MT elicits a chemotactic response. This 
will allow us to more accurately understand the therapeutic potential of manipulating the 
extracellular pool of MT in both inflammation and breast cancer. 
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Figure 7. PLC is Involved in MT-Mediated Chemotaxis. 
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D) 
were pre-incubated with 1µM (A+B) or 5µM (C+D) U73122 for 30 minutes in at 37°C in 5% 
CO2 as determined by dose response and viability experiments (Fig. S3). Media and MT controls 
were pre-incubated under the same conditions in media alone. The bottom chamber was loaded 
with either 10µM MT (MT control and U73122) or media alone (Media control). Boyden 
chamber was assembled using an 8µm (C), 5µM (A), or 3µm pore (B+D) membrane. 8µm pore 
A B 
C D 
Me
dia
 Co
ntr
ol
MT
 Co
ntr
ol
1
M 
U7
31
22
0
50
100
150
Pre-incubated with
av
er
ag
e 
ce
lls
 m
ig
ra
te
d/
w
el
l
JMM 07.18.17
****
****
Me
dia
 Co
ntr
ol
MT
 Co
ntr
ol
1
M 
U7
31
22
0
50
100
150
200
Pre-incubated with
av
er
ag
e 
ce
lls
 m
ig
ra
te
d/
w
el
l
JMM 01.29.18
**
***
Me
dia
 Co
ntr
ol
MT
 Co
ntr
ol
5
M 
U7
31
22
0
50
100
150
Pre-incubated with
av
er
ag
e 
ce
lls
 m
ig
ra
te
d/
w
el
l
JMM 03.23.18
***
****
Messina 34 
 
membranes were coated in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed 
in media, resuspended at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber 
was incubated for 3 hours (A+B+D) or 6 hours (C) at 37°C in 5% CO2. Cells on the underside of 
the membrane were enumerated using a light microscope under 10x. One-way ANOVA followed 
by Tukey’s Multiple Comparisons Test was used to determine statistical significance with * = p 
≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. Graphs are representative of three 
independent experiments. 
 
MEK is Not Involved in MT-Mediated Chemotaxis 
 The mitogen activated protein kinase (MAPK) signaling pathway is involved in many 
cellular processes including development, differentiation, and proliferation. Small G proteins 
known as RAS can phosphorylate mitogen activated protein kinase kinase kinase (MAPKKK) to 
activate it. MAPKK then activates MAPKK (MEK). Following their activation, MEKs can then 
phosphorylate tyrosine and threonine residues on  extracellular signaling regulated kinase (ERK) 
to activate it45. 
 Previous studies conducted in the Lynes Lab have shown that MT can stimulate ERK1/2 
activation, but that this activation only lasts a short amount of time (about two minutes)25. These 
results led to my interest in investigating the role of MEK in MT-mediated chemotaxis. To 
examine MEK’s involvement in MT’s chemotactic signaling cascades, I used PD98059, a small 
molecule inhibitor of MEK. PD98059 binds to the inactive form of MEK to prevent its activation 
by upstream activators46.  
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First, I conducted experiments using Jurkat T cells and primary mouse splenocytes to 
determine the involvement of MEK in MT-mediated chemotaxis in the infiltration of immune 
cells. Jurkat T cells (Figure 8A) and primary mouse splenocytes (Figure 8B) were pre-incubated 
with non-toxic doses of PD98059 (Figure S4). MT control and Media control cells were pre-
incubated in media alone. MT (MT control and PD98059) or media alone (Media control) was 
loaded into the wells of the bottom chamber. After the Boyden Chamber was assembled, cells 
were loaded into the wells of the top chamber. These results show that pre-incubation with 
PD98059 has no effect on the average number of cells migrated per well in both Jurkat T cells 
(Figure 8A) and primary mouse splenocytes (Figure 8B). 
Next, I used mammary tumor cell lines to determine if MEK is involved in MT-mediated 
chemotaxis in breast cancer. MDA-MB-231 cells (Figure 8C) and 419 cells (Figure 8D) were 
pre-incubated with non-toxic doses of PD98059 (Figure S4). MT control and Media control cells 
were pre-incubated in media alone. MT (MT control and PD98059) or media alone (Media 
control) was loaded into the wells of the bottom chamber. After the Boyden Chamber was 
assembled, cells were loaded into the wells of the top chamber. These results show that pre-
incubation with PD98059 has no effect on the average number of cells migrated per well in both 
MDA-MB-231 cells (Figure 8C) and primary mouse splenocytes (Figure 8D). 
 Results from PD98059 experiments show that pre-incubation with this small molecule 
inhibitor does not block MT-mediated chemotaxis in both immune cells and mammary tumor 
cells lines, which suggests that MEK is not involved in MT’s chemotactic signaling pathways.  
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Figure 8. MEK is Not Involved in MT-Mediated Chemotaxis. 
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D) 
were pre-incubated with 50µM, 20µM, or 1µM PD98059 for 1 hour at 37°C in 5% CO2. 
PD98059 concentrations were determined to be non-toxic in viability experiments (Fig. S4). 
Media and MT controls were pre-incubated under the same conditions in media alone. The 
bottom chamber was loaded with either 10µM MT (MT control and PD98059) or media alone 
(Media control). Boyden chamber was assembled using an 8µm (C), 5µM (A), or 3µm pore 
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(B+D) membrane. 8µm pore membranes were coated in 10µg/mL fibronectin at 4°C overnight 
prior to use. Cells were washed in media, resuspended at 2 million cells/mL, and loaded into the 
top chamber. Boyden Chamber was incubated for 3 hours (A+B+D) or 6 hours (C) at 37°C in 
5% CO2. Cells on the underside of the membrane were enumerated using a light microscope 
under 10x. One-way ANOVA followed by Tukey’s Multiple Comparisons Test was used to 
determine statistical significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, and **** = p 
≤ 0.0001. Graphs are representative of three independent experiments. 
 
UC1MT Blocks MT-Mediated Chemotaxis in Breast Cancer Cell Models 
 UC1MT, a monoclonal anti-MT antibody, has been shown to alter the 
immunomodulatory effects of MT in immune cells12,13. Previous studies in the Lynes lab have 
shown that UC1MT can block MT-mediated chemotaxis in both Jurkat T cells and primary 
mouse splenocytes11,25. These results suggested that UC1MT may have therapeutic benefits in 
inflammatory diseases. A subsequent study conducting in a DSS-induced mouse model of colitis 
showed that  UC1MT can reduce immune cell infiltration and inflammation in the gut, indicating 
that it may be a useful therapeutic to treat inflammatory bowel diseases22. Additionally, a study 
conducted in female NOD mice, which serve as a murine model of Type 1 Diabetes showed that 
treatment with UC1MT can prevent the development of Type 1 Diabetes25. While UC1MT has 
shown great promise in the treatment in inflammatory diseases, it has not yet been evaluated in 
breast cancer models. Here, I will examine the ability of UC1MT to block MT-mediated 
chemotaxis in mammary tumor cell lines.  
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 For these experiments, I pre-incubated media, MT, and SDF-1α with UC1MT. Then, I 
loaded the wells of the bottom chamber with either media, MT, or SDF-1α with and without 
UC1MT pre-incubation. After assembly of the Boyden chamber, MDA-MB-231 cells (Figure 
9A) or 419 cells (Figure 9B) were loaded into the wells of the upper chamber. These results 
show that MT pre-incubation with UC1MT results in a decrease in the average number of cells 
migrated per well in both MDA-MB-231 cells (Figure 9A) and 419 cells (Figure 9B), but that 
media or SDF-1α pre-incubation with MT does not result in this effect.  
 The reduction in cell migration seen when MT is pre-incubated with UC1MT suggests 
that UC1MT blocks MT-mediated chemotaxis in mammary tumor cell lines. The fact that SDF-
1α pre-incubation with UC1MT does not result in a reduction in the chemotactic response 
suggests that UC1MT specifically binds to MT to block its chemotactic response. Because 
UC1MT can block MT-mediated chemotaxis in mammary tumor cell lines, it may serve as a 
useful therapeutic to inhibit breast cancer metastasis. 
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Figure 9. UC1MT Blocks MT-Mediated Chemotaxis in Breast Cancer Cell Models. 
Chemoattractants were pre-incubated with 50µg/mL UC1MT or in media alone for 1 hour at 
room temperature and then loaded into the bottom chamber. Boyden chamber was assembled 
using an 8µm pore (A) or 3µm pore (B) membrane. 8µm pore membranes were coated in 
10µg/mL fibronectin at 4°C overnight prior to use. MDA-MB-231 (A) or 419 (B) cells (2million 
cells/mL) were loaded into the top chamber. Boyden Chamber was incubated for 6 hours (A) or 
3 hours (B) at 37°C in 5% CO2. Cells on the underside of the membrane were enumerated using 
a light microscope under 10x. One-way ANOVA followed by Tukey’s Multiple Comparisons 
Test was used to determine statistical significance with * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, and **** = p ≤ 0.0001. Graphs are representative of three independent experiments. 
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Messina 40 
 
Discussion 
 MT expression has been linked to inflammation and many disease phenotypes including 
IBD, diabetes, and many types of cancer15,16,20. Previous studies in the Lynes Lab have shown 
that MT acts as a chemoattractant in lymphocytes and that MT-mediated chemotaxis can be 
blocked by UC1MT, a monoclonal anti-MT antibody11,25. It has also been shown that GPCR 
antagonists Cholera toxin and Pertussis toxin can block MT’s chemotactic effect11, which 
suggests that MT may interact with a GPCR to initiate its chemotactic signaling cascades. Here, I 
have investigated the mechanism by which MT initiates a chemotactic response in both 
inflammation and breast cancer. 
 Breast cancer is the second leading cause of death in women in the United States, with 
one in eight women developing the disease in her lifetime31. Elevated MT expression has been 
linked to inflammation and poor prognosis in patients with breast cancer32–36. MT’s association 
with breast cancer led to the interest in examining the chemotactic potential of MT in breast 
cancer cell models. In these experiments, MDA-MB-231 cells (Figure 3A) and 419 cells (Figure 
3B) served as cell models for breast cancer. Results from these experiments showed that MT acts 
as a chemoattractant in mammary tumor cell lines, which suggests that MT may play a role in 
breast cancer metastasis. This finding prompted exploration of the mechanism by which MT 
initiates the chemotactic response and if UC1MT would block MT-mediated chemotaxis in 
breast cancer cell models. 
 Next, MT peptides were used to determine which region of full-length MT interacts with 
a receptor on the surface of cells to initiate its chemotactic signaling pathways. Previous studies 
in the Lynes Lab examined the ability of MT peptides to block SDF-1α-mediated chemotaxis in 
Jurkat T cells. These studies suggested that the N-terminus of MT is responsible for MT’s 
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binding to its receptor(s)25. While these results indicate that the N-terminus of MT binds to its 
receptor(s) in lymphocytes, it had not yet been explored if the same was true in mammary tumor 
cell lines. For these experiments, I used 419 cells as a model for mammary tumorigenesis. It was 
found that MT peptides are not chemotactic on their own, but that MT1-10, MT4-12, and MT11-20 
can block both MT and SDF-1α-mediated chemotaxis in breast cancer cell models. These results 
suggest that the N-terminus of MT is responsible for binding to its receptor(s) and are consistent 
with the results of experiments conducted in lymphocytes. 
 AMD3100, a small molecule inhibitor of receptor CXCR4, was used to determine the 
involvement of CXCR4 in MT’s chemotactic signaling in mammary tumor cell lines. Studies 
conducted in Jurkat T cells found that MT can block SDF-1α-CXCR4 mediated chemotaxis. 
Subsequently, AMD3100 was used to determine the involvement of CXCR4 in MT-mediated 
chemotaxis in lymphocytes. It was found that AMD3100 can block MT-mediated chemotaxis in 
lymphocytes, which suggests that MT interacts with CXCR4 to initiate its chemotactic 
response25. Similarly, experiments conducted in mammary tumor cell lines show that AMD3100 
blocks MT-mediated chemotaxis (Figure 5). This suggests that CXCR4 is involved in the 
initiation of MT’s signaling cascades in both lymphocytes and breast cancer cell models.  
 MT exposure has been shown to increase F-actin levels in lymphoctyes11, which suggests 
the involvement of the Arp2/3 complex the signaling pathways of MT-mediated chemotaxis. 
Small molecule inhibitor CK-666 was used to evaluate the involvement of the Arp2/3 complex in 
MT-mediated chemotaxis in both lymphocytes and mammary tumor cell lines. CK-666 pre-
incubation blocks MT-mediated chemotaxis immune cells (Figure 6 A+B) and mammary tumor 
cells (Figure 6 C+D), which suggests that the Arp2/3 complex is involved in MT’s chemotactic 
signaling pathways.  
Messina 42 
 
 PLCβ signaling results in an increase in intracellular calcium levels and is known to be 
involved in SDF-1α-CXCR4 mediated chemotaxis43.  U73122, a small molecule inhibitor of 
PLC, was used to examine the role of PLC in MT-mediated chemotaxis.  These experiments 
showed that pre-incubation with U73122 blocks the chemotactic response in both lymphocytes 
(Figure 7 A+B) and breast cancer cell models (Figure 7 C+D). These results suggest that PLC 
signaling is involved in the initiation of MT’s chemotactic response.  
 MEK signaling cascades are involved in many important cellular processes including 
differentiation and proliferation45. While previous studies in the Lynes Lab have shown that MT 
exposure results in short term activation of ERK1/225, the role of this pathway in MT’s 
chemotactic response was not known. PD98059, a small molecule inhibitor of MEK, was used to 
determine the involvement of MEK signaling in MT-mediated chemotaxis. Pre-incubation with 
PD98059 did not block MT’s chemotactic response in both lymphocytes (Figure 8 A+B) and 
mammary tumor cell lines (Figure 8 C+D). These results indicate that MEK is likely not 
involved in MT’s chemotactic signaling pathways. 
 Finally, the ability of UC1MT to block MT-mediated chemotaxis in mammary tumor cell 
lines was examined. Previous studies showed that pre-incubation with UC1MT blocks MT-
mediated chemotaxis in lymphocytes, and that it has therapeutic potential in the treatment of IBD 
and diabetes11,22,25. However, the potential of using UC1MT as a therapeutic for breast cancer 
had not yet been evaluated. Results here show that pre-incubation with UC1MT specifically 
blocks MT-mediated chemotaxis in mammary tumor cell lines (Figure 9). This suggests that 
UC1MT may be a valuable therapeutic to inhibit breast cancer metastasis. 
 Taking the results from all these experiments into account, I have proposed a model for 
the signaling pathways involved in MT-mediated chemotaxis (Figure 10). I propose that 
Messina 43 
 
exogenous MT interacts with CXCR4 (or other unknown receptors) on the surface of the cell. 
This binding event results in the dissociation of Gα and Gβγ. Currently, the role of Gα in MT-
mediated chemotaxis is unknown. Gβγ activates signaling cascades involving PLC and the 
Arp2/3 complex, which results in a chemotactic response. It is of note that Gβγ may initiate 
additional pathways to result in chemotaxis, however we have not explored these possibilities. 
While MEK signaling is known to have important functions in the cell, it is not involved in MT’s 
chemotactic signaling pathways. Finally, UC1MT can bind to exogenous MT to block MT’s 
interaction with its receptor and prevent the chemotactic response.  
These results have provided valuable information regarding the mechanism by which MT 
initiates a chemotactic response, which allows us to further understand MT’s role in 
inflammation and disease processes, and will help us identify other therapeutic targets for 
UC1MT in the future. Furthermore, the fact that UC1MT blocks MT-mediated chemotaxis in 
mammary tumor cell lines suggests that UC1MT may inhibit breast cancer metastasis.  
Next steps for this project include investigating the role of other chemokine receptors, 
such as CXCR7, and the role of other common GPCR signaling cascades in MT-mediated 
chemotaxis. Most importantly, animal studies, likely in a mouse model, must be conducted to 
determine if UC1MT can inhibit mammary tumorigenesis and metastasis to improve patient 
outcomes. 
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Figure 10. Proposed Signaling Pathway of MT-mediated Chemotaxis 
Exogenous MT interacts with chemokine receptor CXCR4. The binding of MT to CXCR4 
results in the dissociation of Gα and Gβγ. The role of Gα in MT-mediated chemotaxis is currently 
unknown. Results from these experiments suggest that Gβγ initiates downstream signaling 
cascades, which result in the activation of both the Arp2/3 complex and phospholipase C (PLC). 
The activation of these complexes initiates cytoskeletal reorganization, which leads to the 
chemotactic response. It is currently unknown if Gβγ activates other downstream signaling 
pathways to initiate MT’s chemotactic response. UC1MT can bind to MT to block its interaction 
with CXCR4 (or other unknown receptors) and inhibit MT’s chemotactic effect. MEK signaling 
does not appear to play a role in MT-mediated chemotaxis. 
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Supplemental Figures 
 
 
 
Figure S1. Dose Response and Cell Viability with AMD3100 Pre-incubation 
MDA-MB-231(A+B) or 419 (C+D) cells were pre-incubated with various concentrations of 
AMD3100 for 30 minutes at 37°C in 5% CO2. Media and MT controls were pre-incubated under 
the same conditions in media alone. After pre-incubation, cell viability (B+D) was calculated 
using a hemocytometer and trypan blue exclusion staining. The bottom chamber was loaded with 
either 10µM MT (MT control and AMD3100) or media alone (Media control). Boyden chamber 
A B 
C D 
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was assembled using an 8µm (A) or 3µm pore (C) membrane. 8µm pore membranes were coated 
in 10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended 
at 2 million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 6 
hours (A) or 3 hours (C) at 37°C in 5% CO2. Cells on the underside of the membrane were 
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s 
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** = 
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001.  
 
 
 
 
Messina 51 
 
 
A B 
C D 
E F 
G H 
Me
dia
 co
ntr
ol
MT
 C
on
tro
l
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6
20
M 
CK
-66
6
1
M 
CK
-66
6
0
50
100
150
Pre-incubated with
JMM 11.27.17
**
*
Ini
tia
l P
os
t H
arv
es
t
Me
dia
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6
20
M 
CK
-66
6
1
M 
CK
-66
6
0
20
40
60
80
100
Pre-incubated with
JMM 11.27.17
92.5 92 91 91 91 92 92
Me
dia
10
0
M 
CK
-66
6 
75
M 
CK
-66
6
50
M 
CK
-66
6 
20
M 
CK
-66
6
1
M 
CK
-66
6 
%
 c
el
l v
ia
bi
lit
y
Me
dia
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6
20
M 
CK
-66
6
1
M 
CK
-66
6
0
20
40
60
80
100
Pre-incubated with
JMM 02.09.18
100 100 100 10098 98
Me
dia
 Co
ntr
ol
MT
 C
on
tro
l
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6
20
M 
CK
-66
6
1
M 
CK
-66
6
0
50
100
150
Pre-incubated with
JMM 02.09.18
**
**
Me
dia
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6 
20
M 
CK
-66
6 
1
M 
CK
-66
6
0
20
40
60
80
100
Pre-incubated with
%
 c
el
l v
ia
bi
lit
y
JMM 11.05.18
95 92 94 94 95 95
Me
dia
 Co
ntr
ol
MT
 C
on
tro
l
10
0
M 
CK
-66
6
75
M 
CK
-66
6
50
M 
CK
-66
6 
20
M 
CK
-66
6 
1
M 
CK
-66
6
0
10
20
30
40
50
Pre-incubated with
JMM 11.05.18
****
****
Me
dia
 Co
ntr
ol
MT
 Co
ntr
ol
10
0
M 
CK
-66
6 
75
M 
CK
-66
6
50
M 
CK
-66
6 
20
M 
CK
-66
6
1
M 
CK
-66
6 
0
20
40
60
Pre-incubated with
JMM 09.15.17
***
**
Messina 52 
 
Figure S2. Dose Response and Cell Viability with CK-666 Pre-incubation 
Jurkat T cells (A+B), Primary Mouse Splenocytes (C+D), MDA-MB-231 cells (E+F), or 419 
cells (G+H) were pre-incubated with various concentrations of CK-666 for 1 hour at 37°C in 5% 
CO2. Media and MT controls were pre-incubated under the same conditions in media alone. The 
bottom chamber was loaded with either 10µM MT (MT control and CK-666) or media alone 
(Media control). After pre-incubation, cell viability (B+D+F+H) was calculated using a 
hemocytometer and trypan blue exclusion staining. Boyden chamber was assembled using an 
8µm (E), 5µM (A), or 3µm pore (C+G) membrane. 8µm pore membranes were coated in 
10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2 
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours 
(A+C+G) or 6 hours (E) at 37°C in 5% CO2. Cells on the underside of the membrane were 
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s 
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** = 
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001. 
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Figure S3. Dose Response and Cell Viability with U73122 Pre-incubation 
Jurkat T cells (A+B), Primary Mouse Splenocytes (C+D), MDA-MB-231 cells (E+F) or 419 
cells (G+H) were pre-incubated with various concentrations of U73122 for 30 minutes at 37°C in 
5% CO2. Media and MT controls were pre-incubated under the same conditions in media alone. 
After pre-incubation, cell viability (B+D+F+H) was calculated using a hemocytometer and 
trypan blue exclusion staining.  The bottom chamber was loaded with either 10µM MT (MT 
control and U73122) or media alone (Media control). Boyden chamber was assembled using an 
8µm (E), 5µM (A), or 3µm pore (C+G) membrane. 8µm pore membranes were coated in 
10µg/mL fibronectin at 4°C overnight prior to use. Cells were washed in media, resuspended at 2 
million cells/mL, and loaded into the top chamber. Boyden Chamber was incubated for 3 hours 
(A+C+G) or 6 hours (E) at 37°C in 5% CO2. Cells on the underside of the membrane were 
enumerated using a light microscope under 10x. One-way ANOVA followed by Tukey’s 
Multiple Comparisons Test was used to determine statistical significance with * = p ≤ 0.05, ** = 
p ≤ 0.01, *** = p ≤ 0.001, and **** = p ≤ 0.0001.  
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Figure S4. Cell Viability with PD98059 Pre-incubation 
Jurkat T cells (A), Primary Mouse Splenocytes (B), MDA-MB-231 cells (C) or 419 cells (D) 
were pre-incubated with various concentrations of PD98059 for 1 hour at 37°C in 5% CO2. 
Media and MT controls were pre-incubated under the same conditions in media alone. After pre-
incubation, cell viability was calculated using a hemocytometer and trypan blue exclusion 
staining. 
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